DTR Stock Overview

An ophthalmic company, engages in developing and commercializing of disruptive diagnostic solutions for eye diseases. More details

DTR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (CA$24M)

My Notes

Capture your thoughts, links and company narrative

DiagnosTear Technologies Inc. Competitors

Aurora Spine

TSXV:ASG

CA$32.1m

Nanalysis Scientific

TSXV:NSCI

CA$36.2m

Perimeter Medical Imaging AI

TSXV:PINK

CA$35.9m

Therma Bright

TSXV:THRM

CA$13.5m

Price History & Performance

Summary of share price highs, lows and changes for DiagnosTear Technologies
Historical stock prices
Current Share Price	CA$0.30
52 Week High	CA$0.71
52 Week Low	CA$0.30
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-57.14%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	DTR	CA Medical Equipment	CA Market
7D	-40.0%	-0.8%	0.9%
1Y	n/a	-14.3%	15.7%

Return vs Industry: Insufficient data to determine how DTR performed against the Canadian Medical Equipment industry.

Return vs Market: Insufficient data to determine how DTR performed against the Canadian Market.

Price Volatility

Is DTR's price volatile compared to industry and market?
DTR volatility
DTR Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	13.7%
Market Average Movement	8.1%
10% most volatile stocks in CA Market	17.3%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: DTR's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine DTR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	bio-light.co.il/diagnos-tear

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing of disruptive diagnostic solutions for eye diseases. It develops TeaRx DES for the identification and monitoring of dry eye syndrome; and TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis. The company is headquartered in Rehovot, Israel.

DiagnosTear Technologies Inc. Fundamentals Summary

How do DiagnosTear Technologies's earnings and revenue compare to its market cap?
DTR fundamental statistics
Market cap	CA$23.52m
Earnings (TTM)	CA$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is DTR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DTR income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$0
Earnings	CA$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did DTR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 00:30
End of Day Share Price	2024/12/30 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DiagnosTear Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution